NanoViricides, Inc. Files Quarterly Report - Reports Further Improved Strong Cash Position Sufficient For Clinical Trials Of Its First Two Drug Candidates

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”), has filed its quarterly report with the Securities and Exchange Commission on Friday, November 14th, in a timely fashion. The submission can be downloaded from the SEC website at http://www.sec.gov/Archives/edgar/data/1379006/000114420414068843/0001144204-14-068843-index.htm. The Company reports that all of its drug development programs are progressing satisfactorily and that it will continue to provide updates as appropriate.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC